Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026
Prognostic significance of incorporating SpO2 recovery time to the 6-minute walk test protocol and to a modified GAP index risk prediction model in patients with idiopathic pulmonary fibrosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yildirim Elif, Tutus Nisanur, Aydogdu Yagmur, Ozmen Ipek
Аннотация
BACKGROUND AND AIM: The prognostic potential of SpO2 recovery time recorded during 6-min walk test (6MWT) remains unexplored in the setting of idiopathic pulmonary fibrosis (IPF). This study aimed to investigate prognostic significance of cardiopulmonary recovery time after the 6MWT and the utility of a modified gender-age-physiology (GAP) index incorporating SpO2 recovery time instead of DLCO as a predictive model in IPF patients.
METHODS: A total of 64 patients with IPF (mean±SD age: 61±10.2 years, 79.7% were males) were included in this retrospective cohort study. Cardiopulmonary recovery time (SpO2 recovery time and heart rate recovery [HRR] time in seconds), GAP index (gender, age, forced vital capacity [FVC] and diffusion capacity [DLCO]) and modified GAP index (gender, age, FVC, SpO2 recovery time) scores were recorded.
RESULTS: SpO2 recovery time and modified GAP index predicted the increased risk of overall adverse events (OR 1.017, p=0.002 and OR 1.667, p<0.010, respectively). SpO2 recovery time at a cut-off value of >160 s (AUC: 0.813, p<0.001) and modified GAP index at a cut-off value of >3.5 (AUC: 0.762, p<0.001) were able to discriminate patients at risk of adverse clinical outcomes. Overall survival (OS) time was significantly longer in patients with SPO2 recovery time <160 s than in those with SPO2 recovery time ≥160 s (mean 24.3 vs. 8.5 months, Log-rank p value <0.001).
CONCLUSIONS: Incorporating SpO2 recovery time to the 6MWT protocol and to a modified GAP index may improve mortality risk prognostication in IPF, supporting the utilization of continuous SpO₂ monitoring and recovery analysis during routine 6MWT.
METHODS: A total of 64 patients with IPF (mean±SD age: 61±10.2 years, 79.7% were males) were included in this retrospective cohort study. Cardiopulmonary recovery time (SpO2 recovery time and heart rate recovery [HRR] time in seconds), GAP index (gender, age, forced vital capacity [FVC] and diffusion capacity [DLCO]) and modified GAP index (gender, age, FVC, SpO2 recovery time) scores were recorded.
RESULTS: SpO2 recovery time and modified GAP index predicted the increased risk of overall adverse events (OR 1.017, p=0.002 and OR 1.667, p<0.010, respectively). SpO2 recovery time at a cut-off value of >160 s (AUC: 0.813, p<0.001) and modified GAP index at a cut-off value of >3.5 (AUC: 0.762, p<0.001) were able to discriminate patients at risk of adverse clinical outcomes. Overall survival (OS) time was significantly longer in patients with SPO2 recovery time <160 s than in those with SPO2 recovery time ≥160 s (mean 24.3 vs. 8.5 months, Log-rank p value <0.001).
CONCLUSIONS: Incorporating SpO2 recovery time to the 6MWT protocol and to a modified GAP index may improve mortality risk prognostication in IPF, supporting the utilization of continuous SpO₂ monitoring and recovery analysis during routine 6MWT.